PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients.

Abstract Hyperbaric oxygen therapy (HBOT) has beneficial effects on avascular necrosis of femoral head (ANFH), but its mechanism of action is still unclear. We investigated if HBOT upregulates serum osteoprotegerin (OPG) and/or inhibits osteoclast activation. 23 patients with unilateral ANFH at stage I, II and III consented to the study: the patients received standard HBOT. Serum OPG levels were obtained at the beginning of HBOT (T0), after 15 sessions (T1), 30 sessions (T2), after a 30-day break (T3), and after 60 sessions (T4). Magnetic resonance imaging (MRI) was obtained at T0 and about one year from the end of HBO treatments. Lesion size was compared between pre- and post-HBOT. 19 patients completed the study. HBOT reduced pain symptoms in all patients. HBOT significantly reduced lesion size in all stage I and II patients and in 2 of 11 stage III patients. HBOT increased serum OPG levels but receptor activator of nuclear factor kappa-B ligand (RANKL) levels did not change.
PMID
Related Publications

Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head.

Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.

Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients.

Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.

Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.

Authors

Mayor MeshTerms

Hyperbaric Oxygenation

Keywords

Avascular necrosis of femoral head

bone remodeling

hyperbaric oxygen therapy

serum osteoprotegerin

serum receptor activator of NF-kB Ligand

Journal Title journal of enzyme inhibition and medicinal chemistry
Publication Year Start




PMID- 28385082
OWN - NLM
STAT- MEDLINE
DA  - 20170407
DCOM- 20170420
LR  - 20170420
IS  - 1475-6374 (Electronic)
IS  - 1475-6366 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Dec
TI  - Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis
      patients.
PG  - 707-711
LID - 10.1080/14756366.2017.1302440 [doi]
AB  - Hyperbaric oxygen therapy (HBOT) has beneficial effects on avascular necrosis of 
      femoral head (ANFH), but its mechanism of action is still unclear. We
      investigated if HBOT upregulates serum osteoprotegerin (OPG) and/or inhibits
      osteoclast activation. 23 patients with unilateral ANFH at stage I, II and III
      consented to the study: the patients received standard HBOT. Serum OPG levels
      were obtained at the beginning of HBOT (T0), after 15 sessions (T1), 30 sessions 
      (T2), after a 30-day break (T3), and after 60 sessions (T4). Magnetic resonance
      imaging (MRI) was obtained at T0 and about one year from the end of HBO
      treatments. Lesion size was compared between pre- and post-HBOT. 19 patients
      completed the study. HBOT reduced pain symptoms in all patients. HBOT
      significantly reduced lesion size in all stage I and II patients and in 2 of 11
      stage III patients. HBOT increased serum OPG levels but receptor activator of
      nuclear factor kappa-B ligand (RANKL) levels did not change.
FAU - Vezzani, Giuliano
AU  - Vezzani G
AD  - a Department of Biomedical Sciences, Physiological Laboratory , University of
      Padova , Padova , Italy.
FAU - Quartesan, Silvia
AU  - Quartesan S
AD  - a Department of Biomedical Sciences, Physiological Laboratory , University of
      Padova , Padova , Italy.
FAU - Cancellara, Pasqua
AU  - Cancellara P
AD  - a Department of Biomedical Sciences, Physiological Laboratory , University of
      Padova , Padova , Italy.
FAU - Camporesi, Enrico
AU  - Camporesi E
AD  - b Anesthesia , Tampa General Hospital; TEAM Health Anesthesia Research Institute 
      , Tampa , FL , USA.
FAU - Mangar, Devanand
AU  - Mangar D
AD  - b Anesthesia , Tampa General Hospital; TEAM Health Anesthesia Research Institute 
      , Tampa , FL , USA.
FAU - Bernasek, Thomas
AU  - Bernasek T
AD  - c Florida Orthopedic Institute , Tampa , FL , USA.
FAU - Dalvi, Prachiti
AU  - Dalvi P
AD  - b Anesthesia , Tampa General Hospital; TEAM Health Anesthesia Research Institute 
      , Tampa , FL , USA.
FAU - Yang, Zhongjin
AU  - Yang Z
AD  - d The Institute for Human Performance , SUNY Upstate Medical University ,
      Syracuse , NY , USA.
FAU - Paoli, Antonio
AU  - Paoli A
AD  - a Department of Biomedical Sciences, Physiological Laboratory , University of
      Padova , Padova , Italy.
FAU - Rizzato, Alex
AU  - Rizzato A
AD  - a Department of Biomedical Sciences, Physiological Laboratory , University of
      Padova , Padova , Italy.
FAU - Bosco, Gerardo
AU  - Bosco G
AD  - a Department of Biomedical Sciences, Physiological Laboratory , University of
      Padova , Padova , Italy.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Enzyme Inhib Med Chem
JT  - Journal of enzyme inhibition and medicinal chemistry
JID - 101150203
RN  - 0 (Osteoprotegerin)
RN  - 0 (RANK Ligand)
RN  - 0 (TNFRSF11B protein, human)
RN  - 0 (TNFSF11 protein, human)
SB  - IM
MH  - Female
MH  - Femur Head Necrosis/*blood/*therapy
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Osteoclasts/drug effects/metabolism
MH  - Osteoprotegerin/*blood/metabolism
MH  - RANK Ligand/*blood
OTO - NOTNLM
OT  - Avascular necrosis of femoral head
OT  - bone remodeling
OT  - hyperbaric oxygen therapy
OT  - serum osteoprotegerin
OT  - serum receptor activator of NF-kB Ligand
EDAT- 2017/04/08 06:00
MHDA- 2017/04/21 06:00
CRDT- 2017/04/08 06:00
AID - 10.1080/14756366.2017.1302440 [doi]
PST - ppublish
SO  - J Enzyme Inhib Med Chem. 2017 Dec;32(1):707-711. doi:
      10.1080/14756366.2017.1302440.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>